Loading stock data…
XFOR
$4.43+0.14 (+3.26%)
Market ClosedLast close May 8
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
X4 Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.43. The stock is currently near its 52-week high of $4.83, remaining 24.1% above its 200-day moving average. Technical signals show neutral RSI of 59 and bullish MACD crossover, explaining why XFOR maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.43
Potential Upside
5%
Whystock Fair Value$4.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$11.67+163.4%
Range$10.00 – $13.00
Fundamentals
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$401.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.51%
Volume
Today's trading volume
427,778
Recent News
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +11.86% and -67.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
One X4 Pharmaceuticals Insider Raised Their Stake In The Previous Year
Insiders were net buyers of X4 Pharmaceuticals, Inc.'s ( NASDAQ:XFOR ) stock during the past year. That is, insiders...
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +38.89% and +53.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
X4 Pharmaceuticals: Q4 Earnings Snapshot
BOSTON (AP) — X4 Pharmaceuticals, Inc. XFOR) on Tuesday reported a loss of $23.9 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 22 cents.